Mangoceuticals (NASDAQ:MGRX) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Mangoceuticals (NASDAQ:MGRX) to a sell rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mangoceuticals in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Mangoceuticals Trading Down 6.6%

Shares of NASDAQ MGRX opened at $0.52 on Friday. The company has a market capitalization of $8.94 million, a P/E ratio of -0.35 and a beta of 2.28. Mangoceuticals has a 12 month low of $0.16 and a 12 month high of $2.75. The stock has a 50 day moving average of $0.40 and a 200-day moving average of $0.43.

Mangoceuticals (NASDAQ:MGRX) last announced its earnings results on Tuesday, May 19th. The company reported ($0.22) earnings per share for the quarter. The firm had revenue of $0.07 million for the quarter. Mangoceuticals had a negative return on equity of 112.00% and a negative net margin of 4,639.13%.

Institutional Trading of Mangoceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of Mangoceuticals during the 4th quarter valued at $35,000. Ikarian Capital LLC purchased a new position in shares of Mangoceuticals in the fourth quarter worth about $102,000. Armistice Capital LLC purchased a new position in shares of Mangoceuticals in the fourth quarter worth about $1,137,000. Geode Capital Management LLC lifted its stake in shares of Mangoceuticals by 35.4% in the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after acquiring an additional 6,928 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of Mangoceuticals in the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 56.72% of the company’s stock.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.